Seattle, WA – August 21, 2025 – Innovation, vision, and investor confidence were on full display at the Keiretsu Forum Investor Capital Expo, held at the Washington Athletic Club in Seattle. At the close of the Expo, attending investors cast their votes for the Most Valued Companies, a recognition that celebrates breakthrough ventures at the forefront of science, technology, and healthcare.
This year’s top honor went to Mussel Polymers, Inc. (MPI), with PredxBio and Inmedix earning second and third place, respectively. Healionics secured the fourth spot in a closely contested vote.
The Winner - Mussel Polymers, Redefining What’s Possible in Materials Science
Mussel Polymers is pioneering a first-of-its-kind innovation: commercial catechol polymers. While over 4,000 U.S. patents have been issued on their applications, MPI is the first company to manufacture and commercialize these polymers for biomedical, defense, and industrial use.
Their polymers bind in extreme environments (underwater or through blood), and even accelerate bone growth. A few of their breakthrough application, namely coatings and adhesives, are now in final testing with the U.S. Navy. They have also developed a biomedical solution that stimulates bone precipitation on teeth, positioned as the first permanent cure for tooth sensitivity.
Runner Up – PredxBio, Where AI Meets Cancer Therapeutics
Cancer treatment is plagued by inefficiency. Therapies succeed just 20% of the time, and 90% of drugs fail before reaching the market. PredxBio is tackling this challenge head-on with its AI-driven spatial biomarker platform, which decodes the hidden complexities of the tumor microenvironment.
By integrating spatial multi-omics—proteomics, transcriptomics, and histology, the company’s technology predicts patient therapy responses with over 90% accuracy. PredxBio is already generating revenue through biopharma service projects, and it is building toward a subscription-based model for clinical and translational insights.
Second-runner Up – Inmedix, Measuring the Biology of Stress
Stress is a silent driver of disease, influencing 60–80% of all U.S. primary care visits, according to JAMA. Yet until now, there has been no precise way to measure it. Inmedix is changing that with CloudHRV™, a 5-minute, point-of-care diagnostic platform that uses next-generation heart rate variability to assess stress biology.
Unlike behavioral measures, Inmedix’s approach identifies the autonomic nervous system’s fight-or-flight response, offering predictive precision in determining therapeutic outcomes. With its platform, physicians can finally distinguish who will and will not respond to specific therapies—transforming treatment pathways for stress-related conditions and autoimmune disease.
Fourth Place – Healionics, Innovating Dialysis Treatment
While just outside the top three, Healionics drew strong investor interest for its STARgraft vascular graft, designed to provide safer, more reliable bloodstream access for dialysis patients. Unlike existing solutions prone to occlusion and infection, STARgraft has shown superior resistance in human studies, potentially extending patient survival and reducing healthcare costs.
A Showcase of Investor-Backed Innovation
The Investor Capital Expo is Keiretsu Forum’s flagship event, where top entrepreneurs present their ventures to a curated audience of active investors. The Most Valued Company awards are decided not by judges, but by investor votes, a signal of real-time market confidence in the company’s promise, innovation, and investor appeal.
“The Expo is where great ideas meet great capital,” said Brianna McDonald, President of Keiretsu Forum Northwest & Rockies. “This year’s winners reflect the kind of innovative solutions that angel investors are eager to support—solutions that can redefine industries and impact millions of lives.”
About Keiretsu Forum Northwest & Rockies
Keiretsu Forum Northwest & Rockies is a region within the global Keiretsu Forum investor network. It includes chapters in Vancouver (Canada), Denver/Boulder, Bellevue, Seattle, Salt Lake City/Boise, and Portland. Keiretsu Forum Northwest & Rockies has more than 400 members and has invested over $500 million since its founding in 2005. For more information, visit www.k4northwest.com
